美国 · 平台与数据 · MarketBeat

Coherus Oncology Reports 89% Response Rate in Early ESCC Study

来源：MarketBeat · 美国 2 小时前

Coherus Oncology (NASDAQ:CHRS) presented interim clinical data for tagmokitug, an investigational therapy designed to target CCR8-positive regulatory T cells, in several…

在 MarketBeat 阅读全文登录后可收藏

MarketNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (www.marketbeat.com)

Coherus Oncology Reports 89% Response Rate in Early ESCC Study

推荐阅读

Glaukos projects $1B 2027 revenue as it raises 2026 net sales guidance to $775M-$785M

Small-Cap Stocks Just Did Something They Haven't Done Since 2018. Is It Finally Time to Buy?

Why Alphabet’s stock could see its worst drop in years after the latest results

Airline groups urge US CDC to reconsider Ebola declaration requirements

Anvil Research Labs CEO flags buy now, pay later’s hidden debt risk

Oracle Forecasts $30B Cash Flow By FY29, Helping Calm AI Capex Concerns, Pushing ORCL Stock To Its Best Day In Five Months

Coherus Oncology Reports 89% Response Rate in Early ESCC Study

分享

推荐阅读

Glaukos projects $1B 2027 revenue as it raises 2026 net sales guidance to $775M-$785M

Small-Cap Stocks Just Did Something They Haven't Done Since 2018. Is It Finally Time to Buy?

Why Alphabet’s stock could see its worst drop in years after the latest results

Airline groups urge US CDC to reconsider Ebola declaration requirements

Anvil Research Labs CEO flags buy now, pay later’s hidden debt risk

Oracle Forecasts $30B Cash Flow By FY29, Helping Calm AI Capex Concerns, Pushing ORCL Stock To Its Best Day In Five Months